Drug Approval | November 16, 2023
Imfinzi plus chemotherapy approved in China as for metastatic biliary tract cancer
Approval based on results from TOPAZ-1 global Phase III trial and a Chinese patient
Approval based on results from TOPAZ-1 global Phase III trial and a Chinese patient
Phase 3 data expected in the second half of 2024
Yesafili, received marketing authorization approval from the European Commission for the European Union
Digitally enabled drug discovery for oncology with potential to accelerate the delivery of new cancer therapies to patients
General Medicine grows 5% and Vaccines 10% led by Shingrix
We are redesigning Bayer to focus only on what’s essential for our mission, ‘Health for all, hunger for none’”
Lack of technology transfer stands out as a formidable barrier
Revenue in the three months ended on Oct. 1 also slipped by 42% to US$ 13.23 billion
RHTC will address a long-standing healthcare access issue for all the local population
Nanoform will receive access to compound libraries and large data sets to undertake STARMAP screening
Subscribe To Our Newsletter & Stay Updated
